WUXI BIO's stock surged 5.01% during intraday trading on Tuesday, following the company's announcement of a significant share repurchase program.
The biopharmaceutical company revealed plans to buy back up to US$400 million worth of its shares in the open market. Management stated that the current market price does not reflect the company's intrinsic value or actual business prospects, viewing the substantial buyback authorization as a strong signal of confidence in its future development outlook.
The board resolution, approved on May 24, 2026, authorizes the repurchase of up to 407 million shares, representing approximately 10% of the total issued shares. The company emphasized that all buybacks will be executed in compliance with applicable regulations and market conditions.